Thus, PD-L1 expression on NSCLC is considered as a predictive factor PD-1/PD-L1 inhibitor mediated immunotherapy and investigation of the regulatory mechanism for PD-L1 expression is valuable for directing future NSCLC immune therapy. Here, CD274 is linked to non-small cell lung carcinoma.